Skip to content

Alto Neuroscience ANRO Earnings yield

Earnings yield at other companies

Xenon Pharmaceuticals logo
Xenon PharmaceuticalsXENE
-6.9%-1.6pp
Acadia Pharmaceuticals logo
Acadia PharmaceuticalsACAD
9.9%+1.6pp
Rapport Therapeutics, Inc. logo
Rapport Therapeutics, Inc.RAPP
-7.2%-2.9pp
Praxis Precision Medicines, Inc. logo
Praxis Precision Medicines, Inc.PRAX
-3.6%-1.7pp
MeiraGTx Holdings plc logo
MeiraGTx Holdings plcMGTX
-25.5%
LBR
LB Pharmaceuticals Inc Common StockLBRX
-5.5%

Other financials

Income statement

See full
Operating income-$27.1M-73.1%
Net income-$26.2M-73.0%
EPS (diluted)-$0.80-42.9%

Balance sheet

See full
Cash & equivalents$264.3M+63.9%
Total debt$20.9M-17.2%
Total equity$243.4M+75.0%
Total assets$276.3M+60.7%

Cash flow

See full
Operating cash flow-$27.1M-63.6%
CapEx$556.0K+2,217%
Free cash flow-$27.6M-66.7%

Valuation

See full
Market cap$874.19M+1,358%
Enterprise value$630.81M-958%

Returns & leverage

See full
Return on equity-38.9%+0.9pp
Debt / equity0.1×-0.1×
Current ratio20.5×-2.0×

Where this comes from

Calculated from Alto Neuroscience’s reported figures.

Based on trailing twelve months.

The official record: Alto Neuroscience’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Alto Neuroscience's earnings yield.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Alto Neuroscience's earnings yield?
Alto Neuroscience (ANRO) reported earnings yield of -10.3% in Q1 2026.
How has Alto Neuroscience's earnings yield changed year-over-year?
Alto Neuroscience's earnings yield increased by 90.4% year-over-year, from -108% to -10.3%.
What does earnings yield mean?
Trailing-twelve-month net income divided by market capitalization at the quarter end — the inverse of the P/E ratio, expressed as a percentage.